Research progress of mitogen-activated protein kinase interacting kinases inhibitors in tumor immunotherapy
10.11665/j.issn.1000-5048.20210403
- VernacularTitle:丝裂原活化蛋白激酶相互作用激酶抑制剂在肿瘤免疫治疗中的研究进展
- Author:
Hong BU
1
;
Jinpei ZHOU
;
Huibin ZHANG
Author Information
1. 中国药科大学新药研究中心
- Publication Type:Journal Article
- Keywords:
MAPK- interacting kinase inhibitor;
eIF4E;
tumor immunotherapy;
advances
- From:
Journal of China Pharmaceutical University
2021;52(4):410-421
- CountryChina
- Language:Chinese
-
Abstract:
With the rise of tumor immunotherapy, small molecule modulators targeting the immune system have become a research hotspot. As well-developed and mature targets, immunity protein kinases have attracted more and more attention. Mitogen-activated protein kinase (MAPK)-interacting kinases (MNKs) are located at the meeting-point of ERK and p38 MAPK signaling pathways, which can phosphorylate eukaryotic translation initiation factor 4E (eIF4E) at the conserved serine 209 exclusively and modulate the translation of mRNA. Herein we review the structural characteristics, mechanism, signaling transduction pathways and close relationship with tumors of MNKs.Meanwhile, the development process and clinical research progress of the MNKs inhibitors reported by different research institutions are introduced in detail.
